Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40299 | 0.98 | TSHR (0.60) | TSHRTP53SRD5A2CA1CA2 | |
| Hydrochloric Acid SCHEMBL2707678 | 0.95 | TSHR (0.57) | TSHRTP53SRD5A2CA1CA2 | |
| Terephthalic Acid SCHEMBL27838889 | 0.88 | TSHR (0.56) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL28958517 | 0.87 | TSHR (0.48) | TSHRTP53SRD5A2CA1CA2 | |
| Benzoic Acid SCHEMBL16418108 | 0.84 | TSHR (0.64) | TSHRTP53SRD5A2ALDH1A1DAO | |
| SCHEMBL13582530 | 0.80 | CES2 (0.48) | CA1CA2CA12CA4CA9 | |
| SCHEMBL3838955 | 0.80 | SRD5A2 (0.48) | SRD5A2CA1CA2CA12CA4 | |
| 4-Methylbenzoic Acid SCHEMBL28049539 | 0.80 | ALDH1A1 (0.63) | TSHRTP53SRD5A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16596001 | 0.79 | CPT1B (0.54) | TSHRTP53CA1CA2CA12 | |
| Terephthalic Acid SCHEMBL29199063 | 0.79 | TSHR (0.92) | TSHRTP53SRD5A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-17 | — | — | US | disclosed |
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4384013-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173485-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023015236-A2 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-02-09 | — | — | WO | disclosed |
| US-10597361-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2020-03-24 | — | — | US | disclosed |
| US-20170349544-A1 | Ethynylbenzene Derivatives | DUKE UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9738604-B2 | Ethynylbenzene derivatives | DUKE UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2266629-B1 | Reagents and methods for radiolabelling of RGD-containing peptides. | HAMMERSMITH IMANET LTD (GB) | 2015-12-09 | — | — | EP | disclosed |
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100069609-A1 | CHEMICAL METHODS AND APPARATUS | ARSTAD ERIK | 2010-03-18 | — | — | US | disclosed |
| US-20090311177-A1 | Radiolabelling Methods | GE HEALTHCARE LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-1934223-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Novartis Pharma AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
| WO-2006009907-A2 | ISOXAZOLIDINE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099433-A1 | COMPOSITION AND METHOD FOR TREATMENT OF GRAM NEGATIVE BACTERIAL INFECTION | NR1H3, NR1H4, NR1H2 | TSHR 211/4885TP53 4246/4885SRD5A2 403/4885 |
| US-10597361-B2 | Ethynylbenzene derivatives | Q6ZSR9, EPX, ZYX | TSHR 1690/4885TP53 1439/4885SRD5A2 2814/4885 |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | QDPR, NQO2, SQLE | TSHR 3896/4885TP53 4709/4885SRD5A2 1939/4885 |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | MAP4K2, MAPKAPK2, MAP3K2 | TSHR 2155/4885TP53 810/4885SRD5A2 2628/4885 |
| US-20250228242-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | APP, APBA1, PRNP | TSHR 4564/4885TP53 2542/4885SRD5A2 4572/4885 |
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | TSHR 1572/4885TP53 780/4885SRD5A2 82/4885 |
| US-20170349544-A1 | Ethynylbenzene Derivatives | Q6ZSR9, EPX, ZYX | TSHR 1690/4885TP53 1439/4885SRD5A2 2814/4885 |
| US-20090311177-A1 | Radiolabelling Methods | CTSV, NGLY1, MAN2B1 | TSHR 273/4885TP53 1082/4885SRD5A2 2914/4885 |
| US-20100069609-A1 | CHEMICAL METHODS AND APPARATUS | C9, KDR, TIE1 | TSHR 240/4885TP53 3213/4885SRD5A2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.